These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10408846)

  • 21. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
    Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
    Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
    Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell activation and death (apoptosis) induced by IL-2: ultrastructural evidence.
    Capelli E; Barni S; Vaccarone R; Fortis C; Nano R
    Anticancer Res; 1996; 16(4A):1775-80. PubMed ID: 8712700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble immunological parameters and early prognosis of renal cell cancer patients.
    Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
    J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
    Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.
    Lissoni P; Fumagalli L; Rovelli F; Brivio F; Di Felice G; Majorca F
    Br J Cancer; 1998 Jun; 77(11):1957-60. PubMed ID: 9667674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
    Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
    Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
    Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
    Int J Biol Markers; 1997; 12(3):134-6. PubMed ID: 9479598
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1.
    Lissoni P; Barni S; Ardizzoia A; Frigerio F; Paolorossi F; Cazzaniga M; Tancini G; Rocco F; Aapro M
    Tumori; 1995; 81(4):261-4. PubMed ID: 8540123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
    Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
    Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
    Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
    Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
    Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
    J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer.
    Lissoni P; Barni S; Tisi E; Rovelli F; Pittalis S; Rescaldani R; Vigoré L; Biondi A; Ardizzoia A; Tancini G
    Eur J Cancer; 1993; 29A(8):1127-32. PubMed ID: 8390845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha.
    Grüngreiff K; Reinhold D; Ansorge S
    Cytokine; 1999 Dec; 11(12):1076-80. PubMed ID: 10623433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.